The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, AI-driven urine test.

Panelists discuss the rapidly evolving endocrine treatment landscape in oncology, emphasizing the shift toward personalized ...

Panelists discuss recent phase 3 trials of novel endocrine agents in advanced breast cancer, highlighting benefits—especially ...

Panelists discuss the ELEVATE trial’s ongoing evaluation of lasofoxifene combined with targeted agents such as ribociclib, ...

Panelists discuss the EMBER-3 trial, which evaluated single-agent oral selective estrogen receptor degrader (SERD) ...

Panelists discuss the SERENA-6 trial evaluating camizestrant, which uniquely enrolled patients with molecularly detected ESR1 ...

Panelists discuss recent phase 3 trials introducing novel endocrine agents such as proteolysis-targeting chimeras (PROTACs) ...

Panelists discuss the expanding array of treatment options for metastatic hormone receptor–positive breast cancer, ...

Panelists discuss that although the use of everolimus has declined with newer targeted therapies, it remains an important ...

Panelists highlight that oral endocrine therapies for hormone receptor-positive breast cancer are generally well tolerated ...

Panelists discuss that for patients with both ESR1 and PIK3CA mutations after progression on CDK4/6 inhibitors, single-agent ...

Panelists discuss that, based on EMERALD trial data, elacestrant provides consistent clinical benefit in metastatic breast cancer regardless of ESR1 mutation allele frequency, supporting the use of ...